{"id":"doi:10.1016/s0140-6736(14)61374-x","kind":"article","title":"Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial","authors":["Frederick Johan Raal","Narimon Honarpour","Dirk Jacobus Blom","G. Kees Hovingh","Feng Xu","Robert C. Scott","Scott M. Wasserman","Evan A. Stein"],"author_count":8,"year":2014,"published":"2014-10-02","venue":"The Lancet","cited_by":730,"doi":"10.1016/s0140-6736(14)61374-x","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1016/s0140-6736(14)61374-x","archive_url":"https://space-kitty.com/papers/doi:10.1016/s0140-6736(14)61374-x","updated":null,"pmid":"25282520","pmcid":null,"openalex_id":"W2023735564","pdf_url":null,"abstract":null,"abstract_license":null,"license":null,"is_open_access":false,"peer_reviewed":null,"categories":["Lipoproteins and Cardiovascular Health"],"details":null,"provenance":"openalex","attribution":"Metadata and citation counts: OpenAlex (CC0).","topics":[{"slug":"cardiovascular-innovation","name":"Cardiovascular Therapeutics","domain_slug":"medicine"}],"cited_in_dossiers":[]}